CA-FOCAL-SYSTEMS
16.3.2022 18:58:07 CET | Business Wire | Press release
On their mission to automate and optimize brick and mortar retail with state-of-the-art AI and deep learning, Focal Systems is proud to announce the launch of the world’s first “Self-Driving Store”-Operating System powered by computer vision and AI, called FocalOS. After 7 years hardening the platform with the largest retailers in the world, Focal's “Self-Driving Store”-Operating System is now Generally Available.
Enabled by AI-powered Shelf Cameras, FocalOS leverages computer vision and deep learning technology to provide real-time shelf digitization. This digitization feeds FocalOS, which automates order writing and ordering, directs stockers to double their productivity, optimizes category management on a per store basis, manages e-comm platforms to eliminate substitutions, tracks productivity per associate to drive further efficiencies, and much more. With FocalOS, corporate leaders can "teleport" into any store from anywhere in the world in seconds to see exactly what their shelves look like and how their stores are performing.
Major retailers have proven >50x ROI with FocalOS, making this the most profitable investment in all of retail technology.
Francois Chaubard, Founder and CEO, will unveil this solution in depth at the FMI Midwinter Conference in Orlando, Fla. on March 29.
Retailers have incredibly challenging jobs. Managing thousands of SKUs, employees, stores and ecommerce, while facing rising labor and supply chain costs and the evergreen battle for market share. Since 2015 our team has worked with leading global retailers to invent and implement AI solutions that drive true innovation, transformative financial returns and happy customers.
-Francois Chaubard - Founder/CEO Focal Systems
Focal has worked with leading retailers across North America, Europe and Australia and deployed more than 50,000 cameras worldwide. This launch enables retailers the ability to run fully automated “Self-Driving Stores" that achieve unprecedented labor efficiencies and sales growth just by setting the store on "Cruise Control" and letting the AI take it from there.
We’re always striving for more ways to improve the shopping experience for our customers. Focal is helping us use technology to improve our on-shelf customer availability, so our customers can find what they are looking for each time they choose to shop in-store with us.”
-Sam Wankowski - Chief Operations Officer, Walmart Canada
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state of the art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”-Operating System that revolutionizes how stores are run. Focal has raised more than $40m to date, and scaled their solutions to three continents and hundreds of stores, with thousands of cameras deployed. The Focal team is a carefully selected group of retail operations and AI experts who together have designed the next generation of operating systems for brick and mortar retail that leverages state-of-the-art AI and retail best practices to automate and optimize brick and mortar and on-line stores today.
Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom